In this article, we review global and national guideline recommendations for the use of LABA/LAMA combination therapy in COPD and synthesize the key evidence for the benefits of LABA/LAMA versus (1) monotherapy, (2) LABA/ICS and (3) LABA/LAMA/ICS, drawing on data from systematic reviews, meta-analyses, and individual studies of LABA/LAMA ...

The clinical manifestations, diagnosis, comorbidities, monitoring, and prognosis of COPD, an overview of COPD management, and the management of refractory COPD and acute exacerbations of COPD are discussed separately. (See "Chronic obstructive pulmonary disease: Diagnosis and staging".)

Mar 11, 2022 · Long-acting muscarinic receptor antagonists (LAMA) are a treatment option for people with COPD. A person with COPD may have emphysema, chronic bronchitis, or both. Emphysema involves the...

For patients with symptoms from COPD, the ATS recommends combination therapy with a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA) based on improved outcomes...

Nov 8, 2022 · This article reviews global and regional/national guideline recommendations for the use of LABA/LAMA in COPD, examines the evidence for the effectiveness and safety of LABA/LAMA versus other therapies and offers a practical guide for clinicians to help ensure appropriate use of LABA/LAMA therapy.

Apr 18, 2018 · The benefits of triple therapy for chronic obstructive pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist...

Global initiative for COPD suggests the use of long acting beta agonists (LABA) and long acting muscarinic antagonists (LAMA) in combination for group B patients with persistent symptoms, group C patients with further exacerbations on LAMA treatment and for group D patients with or without the addition of inhaled corticosteroids (ICSs).

Jun 24, 2020 · Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA) for chronic obstructive pulmonary disease (COPD)...

Apr 29, 2020 · Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD).

Ipratropium is a short-acting muscarinic antagonist (SAMA) which can be used for short-term relief in mild COPD in people who are not using a long-acting antimuscarinic drug. It has a slower onset of action than SABAs with maximal effect occurring 30–60 minutes after use — …